Risk of Contralateral Breast Cancer in CHEK2*1100delC Carriers
Author Information
Author(s): Lene Mellemkjær, Christina Dahl, Jens H. Olsen, Lisbeth Bertelsen, Per Guldberg, Jette Christensen, Anne-Lise Børresen-Dale, Marilyn Stovall, Langholz B, Leonard Bernstein, Charles F. Lynch, Kathleen E. Malone, Ruth W. Haile, Magnus Andersson, David C. Thomas, Patricia Concannon, Marina Capanu, John D. Boice Jr., Jonine L. Bernstein
Primary Institution: Danish Cancer Society
Hypothesis
Does the CHEK2*1100delC mutation increase the risk for asynchronous contralateral breast cancer?
Conclusion
The CHEK2*1100delC mutation is rare among women with contralateral breast cancer and does not significantly increase the risk of developing it.
Supporting Evidence
- Only 1.0% of women with contralateral breast cancer were found to be carriers of the CHEK2*1100delC mutation.
- The study included a large population-based sample of women diagnosed with breast cancer before age 55.
- Carriers who received radiation therapy had a higher rate ratio for developing contralateral breast cancer.
Takeaway
This study looked at whether a specific gene mutation makes women more likely to get breast cancer in the other breast. It found that very few women with this mutation actually had that problem.
Methodology
The study compared 708 women with contralateral breast cancer to 1395 women with unilateral breast cancer, assessing mutation carrier status and treatment history.
Limitations
The rarity of the CHEK2*1100delC mutation limited the ability to study its effects on contralateral breast cancer risk.
Participant Demographics
Women diagnosed with breast cancer before age 55, with cases and controls matched on various factors.
Statistical Information
Confidence Interval
95% CI=0.6–5.4
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website